Literature DB >> 26174493

Kappa Antagonist JDTic in Phase 1 Clinical Trial.

Charles Chavkin1, Diana Martinez2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26174493      PMCID： PMC4613619          DOI： 10.1038/npp.2015.74

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  5 in total

Review 1.  Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress.

Authors:  Kathleen T Brady; Rajita Sinha
Journal:  Am J Psychiatry       Date:  2005-08       Impact factor: 18.112

2.  Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.

Authors:  Stephen L Lowe; Conrad J Wong; Jennifer Witcher; Celedon R Gonzales; Gemma L Dickinson; Robert L Bell; Linda Rorick-Kehn; MaryAnn Weller; Randall R Stoltz; Jane Royalty; Sitra Tauscher-Wisniewski
Journal:  J Clin Pharmacol       Date:  2014-03-26       Impact factor: 3.126

Review 3.  The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.

Authors:  M R Bruchas; B B Land; C Chavkin
Journal:  Brain Res       Date:  2009-08-28       Impact factor: 3.252

Review 4.  Development of κ opioid receptor antagonists.

Authors:  F Ivy Carroll; William A Carlezon
Journal:  J Med Chem       Date:  2013-02-14       Impact factor: 7.446

5.  A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic.

Authors:  Jeffrey J Buda; F I Carroll; Thomas R Kosten; Dennis Swearingen; Bradford B Walters
Journal:  Neuropsychopharmacology       Date:  2015-01-23       Impact factor: 7.853
  5 in total
  12 in total

Review 1.  The impact of sex as a biological variable in the search for novel antidepressants.

Authors:  Alexia V Williams; Brian C Trainor
Journal:  Front Neuroendocrinol       Date:  2018-05-31       Impact factor: 8.606

2.  Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor.

Authors:  Zhong Zheng; Xi-Ping Huang; Thomas J Mangano; Rodger Zou; Xin Chen; Saheem A Zaidi; Bryan L Roth; Raymond C Stevens; Vsevolod Katritch
Journal:  J Med Chem       Date:  2017-04-03       Impact factor: 7.446

3.  Reactive oxygen species (ROS) generation is stimulated by κ opioid receptor activation through phosphorylated c-Jun N-terminal kinase and inhibited by p38 mitogen-activated protein kinase (MAPK) activation.

Authors:  Selena S Schattauer; Andrea Bedini; Floyd Summers; Aiden Reilly-Treat; Mackenzie M Andrews; Benjamin B Land; Charles Chavkin
Journal:  J Biol Chem       Date:  2019-10-01       Impact factor: 5.157

Review 4.  Age as a factor in stress and alcohol interactions: A critical role for the kappa opioid system.

Authors:  Marvin Rafael Diaz; Kathryn Renee Przybysz; Siara K Rouzer
Journal:  Alcohol       Date:  2017-10-12       Impact factor: 2.405

5.  "Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats".

Authors:  Marta Valenza; Eduardo R Butelman; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2017-05-27       Impact factor: 4.530

6.  Pain-Induced Negative Affect Is Mediated via Recruitment of The Nucleus Accumbens Kappa Opioid System.

Authors:  Nicolas Massaly; Bryan A Copits; Adrianne R Wilson-Poe; Lucia Hipólito; Tamara Markovic; Hye Jean Yoon; Shiwei Liu; Marie C Walicki; Dionnet L Bhatti; Sunil Sirohi; Amanda Klaas; Brendan M Walker; Rachael Neve; Catherine M Cahill; Kooresh I Shoghi; Robert W Gereau; Jordan G McCall; Ream Al-Hasani; Michael R Bruchas; Jose A Morón
Journal:  Neuron       Date:  2019-03-13       Impact factor: 17.173

7.  Kappa Opioid Receptors Drive a Tonic Aversive Component of Chronic Pain.

Authors:  Shiwei Steve Liu; Sarah Pickens; Nicole E Burma; Ines Ibarra-Lecue; Hongyan Yang; Lihua Xue; Chris Cook; Joshua K Hakimian; Amie L Severino; Lindsay Lueptow; Kristina Komarek; Anna M W Taylor; Mary C Olmstead; F Ivy Carroll; Caroline E Bass; Anne M Andrews; Wendy Walwyn; Tuan Trang; Christopher J Evans; Frances M Leslie; Catherine M Cahill
Journal:  J Neurosci       Date:  2019-03-12       Impact factor: 6.167

Review 8.  Allostatic Mechanisms of Opioid Tolerance Beyond Desensitization and Downregulation.

Authors:  Catherine M Cahill; Wendy Walwyn; Anna M W Taylor; Amynah A A Pradhan; Christopher J Evans
Journal:  Trends Pharmacol Sci       Date:  2016-09-23       Impact factor: 14.819

Review 9.  The Role of the Kappa Opioid System in Comorbid Pain and Psychiatric Disorders: Function and Implications.

Authors:  Miao-Jin Ji; Jiao Yang; Zhi-Qiang Gao; Liang Zhang; Chao Liu
Journal:  Front Neurosci       Date:  2021-02-24       Impact factor: 4.677

10.  Major Depressive Disorder and Kappa Opioid Receptor Antagonists.

Authors:  Wei Li; Huijiao Sun; Hao Chen; Xicheng Yang; Li Xiao; Renyu Liu; Liming Shao; Zhuibai Qiu
Journal:  Transl Perioper Pain Med       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.